Similarly, a meta-analysis of 12 clinical trials using recombinant G-CSF and GM-CSF as sepsis treatments in humans found a significant improvement in the rate of infection clearance, but failed to demonstrate any significant improvements in mortality [92]. This evidence concerns the gene CSF3 and infection.